fbh1 Antibody

What is FBH1 and why is it significant for DNA damage research?

FBH1 (F-box helicase 1) is a 3'-5' DNA helicase with a molecular mass of approximately 120 kDa that possesses ATPase activity and functions as a substrate-recognition component of the SCF(FBH1) E3 ubiquitin ligase complex . Its significance stems from its dual role in genome maintenance: it acts as an anti-recombinogenic helicase by preventing excessive strand exchange during homologous recombination (HR) and promotes RAD51 filament dissolution from stalled forks . Additionally, FBH1 promotes cell death and DNA double-strand breakage in response to replication stress, collaborating with MUS81 to induce endonucleolytic DNA cleavage following prolonged replication stress . This makes FBH1 a critical molecule for understanding DNA damage response pathways and genome stability mechanisms.

What types of FBH1 antibodies are currently available for research applications?

Currently, researchers have access to several types of FBH1 antibodies. Mouse monoclonal antibodies against human FBH1, such as clone 2353C1a (ab58881), have been validated for Western blotting applications with recombinant human FBH1 fragments . Additionally, polyclonal antibodies raised in chickens against FBH1 fragment spanning amino acids 1-484 have been developed and affinity-purified for research use . These antibodies enable detection of endogenous FBH1 in various experimental settings, including immunofluorescence microscopy for visualization of FBH1 localization at DNA damage sites.

How does FBH1 interact with PCNA and what implications does this have for antibody-based studies?

FBH1 interacts with PCNA (Proliferating Cell Nuclear Antigen) through both a classical PIP-box and an APIM motif . This interaction is critical for FBH1 recruitment to replication factories and DNA damage sites . In immunofluorescence studies, FBH1 colocalizes with PCNA in approximately 20-25% of unperturbed cells, particularly during S-phase . After DNA damage, FBH1 accumulates at sites of local UV irradiation within 1 hour, where it co-localizes with PCNA and persists for at least 3 hours . Importantly, this PCNA interaction also regulates FBH1 degradation via the CRL4(Cdt2)-PCNA pathway through a PIP degron, creating a dynamic regulatory mechanism . These interactions must be considered when designing experiments using FBH1 antibodies, particularly when studying chromatin-bound fractions or damage-induced responses.

What are the optimal protocols for detecting FBH1 localization after DNA damage using antibodies?

For optimal detection of FBH1 localization after DNA damage, researchers should:

• Generate localized DNA damage using techniques such as UV laser microirradiation or local UV irradiation through filters

• Fix cells at appropriate timepoints (1-3+ hours post-damage) to capture the dynamic response

• Use proper extraction methods to visualize chromatin-bound FBH1, as it accumulates at damage sites

• Co-stain with established DNA damage markers like γ-H2AX, RPA, or PCNA to confirm damage localization

• Include EdU labeling to identify S-phase cells, as FBH1 forms foci during S-phase even without exogenous damage

• Use appropriate controls including undamaged cells and FBH1-depleted cells to confirm antibody specificity

• Consider proteasome inhibitors to prevent damage-induced degradation of FBH1, especially in later timepoints

This approach enables robust visualization of FBH1 recruitment to sites of DNA damage or replication stress in a manner dependent on its helicase activity.

How can researchers effectively distinguish between helicase-dependent and F-box-dependent functions of FBH1?

To distinguish between helicase-dependent and F-box-dependent functions of FBH1, researchers should implement a comprehensive approach:

• Design complementation experiments using FBH1-depleted cells expressing:

  • Wild-type FBH1

  • Helicase-dead mutant (D698N)

  • F-box mutant

• Analyze multiple FBH1-dependent phenotypes:

  • RAD51 focus formation and chromatin association

  • ssDNA generation measured by RPA2 chromatin binding or BrdU staining under non-denaturing conditions

  • DNA damage signaling via γ-H2AX formation

  • Cell survival after replication stress using clonogenic assays

• Use domain-specific antibodies if available, or epitope-tagged constructs with confirmed functionality

Research has shown that FBH1's helicase activity is essential for efficient induction of DSBs and apoptosis specifically in response to DNA replication stress . For instance, while HU resistance was rescued by expression of wild-type FBH1, the helicase-dead FBH1(D698N) mutant failed to restore this phenotype . Similarly, FBH1 recruitment to DNA damage sites depends fully on its helicase activity and partially on its conserved F-box .

What methodological approaches are most effective for studying FBH1's role in dismantling RAD51 filaments?

To effectively study FBH1's role in dismantling RAD51 filaments, researchers should consider the following methodological approaches:

Studies have demonstrated that FBH1 depletion increases levels of chromatin-associated RAD51 and causes unscheduled sister chromatid exchange, while elevated FBH1 levels impair RAD51 recruitment to ssDNA and suppress HR . Additionally, biochemical evidence shows that FBH1 can directly disrupt RAD51 filaments in vitro , supporting its role as a negative regulator of homologous recombination.

How should researchers interpret changes in FBH1 levels after DNA damage in experimental systems?

Interpretation of FBH1 level changes after DNA damage requires careful consideration of several factors:

• FBH1 is targeted for degradation by the CRL4(Cdt2)-PCNA pathway via a PIP degron after DNA damage, suggesting a regulatory mechanism to control its activity

• During experimental analysis, researchers should:

  • Examine both total protein levels and chromatin-bound fractions, as these pools may change differently

  • Use proteasome inhibitors to distinguish degradation from reduced synthesis

  • Include time course analyses to capture the dynamic regulation of FBH1

  • Consider cell cycle position, as FBH1 regulation may vary in different phases

• For Western blot analysis of FBH1 after DNA damage:

  • Include appropriate loading controls for each fraction

  • Consider analyzing both soluble and chromatin-bound fractions

  • Account for cell cycle distributions in the population

The expression of non-degradable FBH1 mutants impairs the recruitment of TLS polymerase eta to chromatin in UV-irradiated cells, suggesting that FBH1 degradation is necessary for proper coordination between HR and TLS pathways .

What controls are essential when studying the relationship between FBH1 and replication stress?

When investigating FBH1's role in replication stress responses, essential controls include:

• Damage-specific controls:

  • Compare different replication stress inducers (HU, UV, etc.) as they may elicit different FBH1 responses

  • Include DNA damaging agents that do not primarily cause replication stress

• Genetic controls:

  • Use FBH1 knockdown/knockout cells with appropriate rescue constructs

  • Include helicase-dead mutant (D698N) to distinguish helicase-dependent functions

  • Consider knockdown of interaction partners like PCNA to confirm relationship specificity

• Technical controls:

  • For HU experiments, test different concentrations and exposure times

  • When releasing cells from HU block, monitor recovery through markers like RPA2 foci, BrdU positivity, and γ-H2AX foci

  • Track DNA synthesis through EdU incorporation to confirm impact on replication

• Cell death measurements:

  • Include cleaved Caspase 3 staining to monitor apoptosis

  • Perform clonogenic survival assays to assess long-term cellular outcomes

Research has demonstrated that FBH1 plays a critical role in promoting DSB formation and apoptosis specifically after replication stress, with FBH1-depleted cells showing rapid disappearance of RPA2 foci, BrdU positivity, and γ-H2AX foci after release from HU block, indicating faster recovery and improved survival .

How can researchers investigate the complex interplay between FBH1, RAD51, and PCNA in DNA damage responses?

To study the complex interplay between FBH1, RAD51, and PCNA in DNA damage responses, researchers should implement multifaceted approaches:

• Temporal analysis:

  • Conduct time course experiments to determine the sequential recruitment and removal of each protein at damage sites

  • Use live-cell imaging with fluorescently tagged proteins if available

• Interaction studies:

  • Perform co-immunoprecipitation experiments before and after damage induction

  • Consider proximity ligation assays (PLA) to detect protein interactions in situ

  • Analyze how mutations in one protein affect interactions with others

• Functional interdependencies:

  • Deplete each protein individually and examine effects on the others' localization

  • Use domain-specific mutants to map interaction requirements

  • Assess how PCNA modifications (ubiquitination, SUMOylation) affect FBH1 and RAD51

• Combined analysis:

  • Triple immunostaining to visualize all three proteins simultaneously

  • Correlate protein dynamics with functional outcomes (HR efficiency, cell survival)

Research has established that PCNA is critical for FBH1 recruitment to replication factories or DNA damage sites , while FBH1's anti-recombinase activity is partially dependent on its interaction with PCNA . FBH1 limits RAD51 recruitment to chromatin , and after performing its function, FBH1 is degraded in a PCNA-dependent manner to facilitate TLS pathway activation , revealing a sophisticated regulatory network.

Why might researchers observe inconsistent results when studying FBH1 in different cell types or experimental systems?

Inconsistencies in FBH1 studies across different experimental systems may arise from several factors:

• Cell type-specific variations:

  • Expression levels of FBH1 and its interacting partners may vary between cell lines

  • Genetic background differences, particularly in DNA repair pathways (p53 status, HR proficiency)

  • Cell cycle distribution variations affecting FBH1 activity

• Methodological differences:

  • Antibody selection and validation approaches

  • Knockdown efficiency vs. knockout systems

  • Overexpression artifacts vs. endogenous studies

• Experimental conditions:

  • Type and dose of DNA damaging agents

  • Timing of analysis (FBH1 shows dynamic regulation)

  • Acute vs. chronic stress conditions

For example, while mouse Fbh1-deficient embryonic stem cells display a moderate increase in Rad51 localization to DNA damage sites, they do not show HR defects or sensitivity to DNA damaging agents . In contrast, human FBH1 depletion increases chromatin-associated RAD51 and causes unscheduled sister chromatid exchange , highlighting species-specific or cell type-specific differences in FBH1 function.

What are the key considerations when evaluating FBH1 antibody specificity for research applications?

When evaluating FBH1 antibody specificity, researchers should consider:

• Validation controls:

  • Western blot analysis showing a band at the expected molecular weight (~120 kDa)

  • Reduced or absent signal in FBH1-depleted or knockout cells

  • Appropriate reactivity with recombinant FBH1 protein or fragments

• Application-specific validation:

  • For immunofluorescence, verify that staining patterns match expected localization (nuclear, with S-phase foci, recruitment to damage sites)

  • For immunoprecipitation, confirm pull-down of known interacting partners

  • For ChIP applications, include appropriate controls for chromatin association

• Cross-reactivity assessment:

  • Test in cell types with different FBH1 expression levels

  • Consider testing in FBH1 knockout cells as negative controls

  • Evaluate potential cross-reactivity with related helicases

• Epitope considerations:

  • Understand which domain of FBH1 the antibody recognizes

  • Consider how post-translational modifications might affect epitope recognition

  • For functional studies, ensure epitope recognition doesn't interfere with protein function

When generating polyclonal antibodies against FBH1, researchers have used approaches such as raising antibodies in chickens against an FBH1 fragment spanning amino acids 1-484, followed by affinity purification using a column conjugated with the antigen , demonstrating a rigorous approach to antibody generation.

How can FBH1 antibodies contribute to understanding the coordination between HR and TLS pathways?

FBH1 antibodies can provide valuable insights into HR and TLS pathway coordination through several research approaches:

• Temporal resolution studies:

  • Track FBH1, RAD51 (HR marker), and TLS polymerases (e.g., Pol η) dynamics after DNA damage

  • Monitor FBH1 degradation kinetics in relation to TLS activation

• Chromatin association analysis:

  • Compare chromatin-bound fractions of FBH1, HR proteins, and TLS factors across time

  • Assess how non-degradable FBH1 mutants affect TLS polymerase recruitment

• Structure-function investigations:

  • Use domain-specific antibodies to determine if specific FBH1 domains are required for pathway coordination

  • Analyze post-translational modifications of FBH1 that might regulate pathway switching

Recent findings demonstrate that expression of non-degradable FBH1 mutant impairs the recruitment of TLS polymerase eta to chromatin in UV-irradiated cells , suggesting that after DNA damage, FBH1 might be required to restrict HR and then must be degraded by the Cdt2-proteasome pathway to facilitate the TLS pathway . This indicates a sophisticated regulatory mechanism where FBH1 serves as a molecular switch between repair pathways.

What emerging technologies might enhance FBH1 antibody applications in DNA repair research?

Emerging technologies that could enhance FBH1 antibody applications include:

• Advanced imaging approaches:

  • Super-resolution microscopy to precisely locate FBH1 at damage sites relative to other repair factors

  • Live-cell imaging with endogenously tagged FBH1 to track real-time dynamics

  • Correlative light and electron microscopy to link FBH1 localization with chromatin ultrastructure

• Proximity-based technologies:

  • BioID or APEX2 proximity labeling to map FBH1's protein neighborhood at damage sites

  • FRET-based sensors to detect FBH1 conformational changes upon DNA binding or protein interactions

  • Proximity ligation assays to visualize specific protein-protein interactions in situ

• Single-molecule techniques:

  • DNA curtains to directly visualize FBH1 activity on DNA substrates

  • Single-molecule pull-down (SiMPull) to analyze complex composition and stoichiometry

• Multi-omics integration:

  • ChIP-seq with FBH1 antibodies to map genomic locations of FBH1 binding

  • Integration with proteomics data to connect FBH1 function with global cellular responses

These technologies could significantly advance our understanding of FBH1's dynamic behavior in DNA repair processes and its role in maintaining genome stability.

How might understanding FBH1 function contribute to development of targeted therapies for DNA repair deficiencies?

Understanding FBH1 function could contribute to targeted therapy development through several avenues:

• Synthetic lethality approaches:

  • FBH1 inhibition might sensitize HR-deficient cancers to replication stress

  • FBH1 manipulation could enhance effectiveness of existing DNA-damaging therapies

• Replication stress modulation:

  • FBH1 inhibition might protect normal cells from chemotherapy-induced replication stress

  • FBH1 activation might increase cancer cell death after replication stress

  • Precise targeting of FBH1's pro-apoptotic function in replication stress response could selectively kill cancer cells

• Pathway coordination:

  • Manipulating FBH1 degradation could alter the balance between HR and TLS pathways

  • This could be exploited in contexts where one pathway is already compromised

• Biomarker development:

  • FBH1 antibodies could help identify tumors with altered FBH1 expression or localization

  • This could guide selection of appropriate DNA-damaging treatments